complement-dependent neutrophil mediated cytotoxicity - Allie (アリー): 展開形からの検索結果

A Search Service for Abbreviation / Long Form

■検索結果 - 展開形 : complement-dependent neutrophil mediated cytotoxicity

検索条件

検索語：complement-dependent neutrophil mediated cytotoxicity

検索方法：完全一致

主な研究分野:

結果

展開形: C-dependent neutrophil-mediated cytotoxicity

出現頻度: 113

対応する略語の数: 5

No.

略語

主な研究分野

共起略語

PubMed/MEDLINE情報 (発表年, 題目)

1

NS-NSCLC

(73回)

新生物, 腫瘍

(40回)

PFS(27回)

OS(25回)

HR(14回)

2011Safety and efficacy of first-line bevacizumab with chemotherapy in Asian patients with advanced nonsquamous NSCLC: results from the phase IV MO19390 (SAiL) study.

2

NSqNSCLC

(21回)

新生物, 腫瘍

(12回)

OS(12回)

PFS(10回)

CI(4回)

2013Pemetrexed and cisplatin for advanced non-squamous non-small cell lung cancer in Japanese patients: phase II study.

3

non-sq NSCLC

(17回)

新生物, 腫瘍

(8回)

PFS(10回)

OS(9回)

CI(6回)

2014Phase II trial of carboplatin and pemetrexed as first-line chemotherapy for non-squamous non-small cell lung cancer, and correlation between the efficacy/toxicity and genetic polymorphisms associated with pemetrexed metabolism: Hokkaido Lung Cancer Clinical Study Group Trial (HOT) 0902.

4

mNSCLC

(1回)

Health Services

公共医療

(1回)

ASP(1回)

mCRC(1回)

NNC(1回)

2025Cost-efficiency and expanded access modeling of conversion to biosimilar bevacizumab in metastatic colorectal and non-squamous non-small cell lung cancer in Medicare.

5

non-squamous-NSCLC

(1回)

新生物, 腫瘍

(1回)

RECIST(1回)

VEGFRIs(1回)

2023Modified response evaluation criteria in solid tumors: A better response evaluation criteria for patients with non-squamous non-small cell lung cancer after bevacizumab treatment.